In the past week, GOSS stock has gone down by -7.18%, with a monthly decline of -14.78% and a quarterly plunge of -32.82%. The volatility ratio for the week is 9.33%, and the volatility levels for the last 30 days are 7.68% for Gossamer Bio Inc. The simple moving average for the past 20 days is -8.71% for GOSS’s stock, with a -47.42% simple moving average for the past 200 days.
Is It Worth Investing in Gossamer Bio Inc. (NASDAQ: GOSS) Right Now?
while the 36-month beta value is 1.20.Analysts have differing opinions on the stock, with 6 analysts rating it as a “buy,” 0 as “overweight,” 4 as “hold,” and 1 as “sell.”
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
The average price point forecasted by analysts for Gossamer Bio Inc. (GOSS) is $5.31, which is $4.39 above the current market price. The public float for GOSS is 220.17M, and currently, short sellers hold a 8.98% ratio of that floaft. The average trading volume of GOSS on September 18, 2023 was 2.40M shares.
GOSS) stock’s latest price update
The stock of Gossamer Bio Inc. (NASDAQ: GOSS) has increased by 5.12 when compared to last closing price of 0.88.Despite this, the company has seen a loss of -7.18% in its stock price over the last five trading days. Business Wire reported 2023-09-07 that SAN DIEGO–(BUSINESS WIRE)–Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that data from its functional respiratory imaging, or FRI, sub-study of the successful Phase 2 TORREY Study of seralutinib in patients with PAH will be presented at the European Respiratory Society International Congress 2023. Dr. Roham Zamanian, Profes.
Analysts’ Opinion of GOSS
Many brokerage firms have already submitted their reports for GOSS stocks, with UBS repeating the rating for GOSS by listing it as a “Neutral.” The predicted price for GOSS in the upcoming period, according to UBS is $1.25 based on the research report published on July 27, 2023 of the current year 2023.
GOSS Trading at -24.20% from the 50-Day Moving Average
After a stumble in the market that brought GOSS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.68% of loss for the given period.
Volatility was left at 7.68%, however, over the last 30 days, the volatility rate increased by 9.33%, as shares sank -9.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -28.09% lower at present.
During the last 5 trading sessions, GOSS fell by -7.18%, which changed the moving average for the period of 200-days by -89.46% in comparison to the 20-day moving average, which settled at $1.0033. In addition, Gossamer Bio Inc. saw -57.59% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GOSS starting from Aranda Richard, who sale 1,814 shares at the price of $1.29 back on Jun 22. After this action, Aranda Richard now owns 197,574 shares of Gossamer Bio Inc., valued at $2,340 using the latest closing price.
Giraudo Bryan, the COO/CFO of Gossamer Bio Inc., purchase 55,000 shares at $1.02 during a trade that took place back on Apr 04, which means that Giraudo Bryan is holding 125,990 shares at $56,094 based on the most recent closing price.
Stock Fundamentals for GOSS
The total capital return value is set at -80.27, while invested capital returns managed to touch -87.05.
Based on Gossamer Bio Inc. (GOSS), the company’s capital structure generated 1,869.16 points at debt to equity in total, while total debt to capital is 94.92. Total debt to assets is 82.86, with long-term debt to equity ratio resting at 1,748.31. Finally, the long-term debt to capital ratio is 88.78.
The liquidity ratio also appears to be rather interesting for investors as it stands at 5.32.
Conclusion
In a nutshell, Gossamer Bio Inc. (GOSS) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
